IMVARIA Inc. Their vision is to transform clinical decision-making into data science using AI-driven digital biomarker solutions. By leveraging AI, machine learning, and deep-learning models, IMVARIA aims to help physicians accurately and rapidly diagnose patients, potentially reducing the need for invasive biopsy testing.

IMVARIA's technology will be showcased in four presentations at the American Thoracic Society 2023 International Conference, highlighting their ability to optimize patient outcomes through novel digital biomarkers. Their lead digital biomarker program, Fibresolve, uses AI to analyze CT imaging for specific patterns and has received FDA Breakthrough Device Designation for non-invasive diagnosis of interstitial lung disease, including idiopathic pulmonary fibrosis. IMVARIA's Digital Biomarker Lab operates as a centralized, cloud-based lab, handling data to deliver reports on cases within minutes.

IMVARIA works with clinicians, health systems, and life sciences to improve clinical diagnostics, advance research in serious diseases, and optimize clinical trials